Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

BACKGROUND/OBJECTIVES: To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course. SUBJECTS/METHODS: This study was an international, prospective, randomized, double-...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sunil S., Lally, David R., Hsu, Jason, Wykoff, Charles C., Eichenbaum, David, Heier, Jeffrey S., Jaffe, Glenn J., Westby, Keith, Desai, Dhaval, Zhu, Liansheng, Khanani, Arshad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686386/
https://www.ncbi.nlm.nih.gov/pubmed/36964259
http://dx.doi.org/10.1038/s41433-023-02497-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686386/
https://www.ncbi.nlm.nih.gov/pubmed/36964259
http://dx.doi.org/10.1038/s41433-023-02497-w

Ejemplares similares